Medidata Solutions announced that it has expanded its accreditation program for services partners to include seven additional Medidata products, in response to the increasing global demand for its product portfolio. The accreditations are available through the Medidata Partner Program, which selects and enables contract research organizations (CROs) and other service providers to manage sponsors’ clinical trials using Medidata products.
Since 2007, Medidata has offered partner accreditations for its Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) system, providing end user training, user and site administration, study build, reporting, outputs, and migration services. With the growing number of global research sponsors implementing a range of Medidata products across the clinical development process, Medidata added the following accreditation options for Medidata Services Partners:
Medidata Balance™—Partners are enabled to provide randomization and trial supply management (RTSM) services using this system. Investigators can access one system—Medidata Rave—for EDC, randomization, and supply management.
Medidata Coder™—Partners offer medical coding services using this centralized enterprise coding solution that is easily integrated with any source system for accelerated coding activities.
Medidata CTMS™—Partners can offer trial management services using modular and flexible tools for study planning, start-up and conduct, along with financial management and trial monitoring. Sponsors benefit from faster site payments, more timely monitor reporting and better visibility into trial milestones.
Medidata Designer®—Partners offer study design services leveraging this study and protocol design solution based on reusable libraries and structured design information to improve protocol quality, expedite EDC setup and reduce amendments.
Medidata Grants Manager®—Partners use this trial budgeting tool for access to the PICAS® database of negotiated costs from investigator grants to rapidly provide customers with accurate trial forecasts and budgets for clinical trials.
Medidata Rave Safety Gateway—Partners automate their customers’ EDC-to-safety-system data transfers using this system to expedite case triage with improved accuracy and completeness of SAE case data, reduce data reconciliation activities and eliminate error-prone phone, paper and fax processes.
Medidata Rave Targeted SDV—Partners can offer more efficient monitoring services using this EDC-based solution to execute targeted (risk-based) source document verification.
Medidata trains, accredits, and supports Medidata Services Partners on its technology so partners can cost-effectively implement and use Medidata products for sponsors’ studies. To become accredited, an organization must first complete required training with a Medidata services team to learn best practices for implementing and using the product. After demonstrating know-how and experience with specific products, Medidata recognizes the organization as a Medidata Services Partner.
Medidata first announced its channel partner program in April 2005 to enable select CROs and other service providers to offer services in support of Medidata products. Since then, the program has grown to include about 30 partners, ranging from smaller clinical consultancies to large, global CROs.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.